Altimmune (NASDAQ:ALT) Price Target Raised to $25.00 at HC Wainwright

Altimmune (NASDAQ:ALT) had its target price raised by investment analysts at HC Wainwright from $12.00 to $25.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Several other equities analysts have also recently weighed in on ALT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a report on Monday, December 29th. Wall Street Zen downgraded Altimmune from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. B. Riley Financial reduced their price objective on shares of Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday, March 6th. Barclays assumed coverage on shares of Altimmune in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 target price for the company. Finally, William Blair reaffirmed a “market perform” rating on shares of Altimmune in a report on Thursday, March 5th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Altimmune has an average rating of “Hold” and an average target price of $19.20.

Altimmune Stock Performance

Shares of NASDAQ:ALT traded up $0.14 on Monday, reaching $3.64. 868,177 shares of the company’s stock were exchanged, compared to its average volume of 4,656,449. The company has a fifty day moving average of $4.50 and a 200-day moving average of $4.30. Altimmune has a twelve month low of $2.90 and a twelve month high of $7.73. The company has a market capitalization of $472.80 million, a price-to-earnings ratio of -3.58 and a beta of 0.13. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.15.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 49.35%. On average, research analysts predict that Altimmune will post -1.35 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director John Gill purchased 12,500 shares of the stock in a transaction dated Tuesday, December 23rd. The stock was bought at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the completion of the acquisition, the director owned 12,500 shares of the company’s stock, valued at approximately $51,250. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jerome Benedict Durso acquired 20,000 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were purchased at an average cost of $3.54 per share, for a total transaction of $70,800.00. Following the acquisition, the chief executive officer owned 32,500 shares in the company, valued at $115,050. This represents a 160.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have purchased 55,527 shares of company stock valued at $213,778. 4.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Altimmune

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in Altimmune by 13.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock worth $7,489,000 after buying an additional 228,995 shares during the period. Brown Wealth Management LLC raised its stake in shares of Altimmune by 131.0% during the second quarter. Brown Wealth Management LLC now owns 231,083 shares of the company’s stock valued at $894,000 after acquiring an additional 131,059 shares during the last quarter. Intech Investment Management LLC lifted its holdings in shares of Altimmune by 102.9% during the second quarter. Intech Investment Management LLC now owns 144,890 shares of the company’s stock worth $561,000 after purchasing an additional 73,482 shares during the period. Jefferies Financial Group Inc. lifted its holdings in shares of Altimmune by 40.0% during the second quarter. Jefferies Financial Group Inc. now owns 35,000 shares of the company’s stock worth $135,000 after purchasing an additional 10,000 shares during the period. Finally, Steward Partners Investment Advisory LLC grew its stake in shares of Altimmune by 43.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 213,384 shares of the company’s stock worth $826,000 after purchasing an additional 64,175 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.